AzurRx BioPharma, Inc. logo
AzurRx BioPharma, Inc. AZRX

AzurRx BioPharma, Inc. Net Income | AZRX

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income AzurRx BioPharma, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-32.7 T -15.2 M -13.5 M -11.1 M -14.6 M -5.93 M - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-5.93 M -32.7 T -5.45 T

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
-2.4 M - -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
-84.3 M - - $ 1.77 B usaUSA
Biofrontera AG Biofrontera AG
BFRA
-13 M - -8.24 % $ 105 M germanyGermany
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
-37.3 M - -6.97 % $ 657 M usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
152 M - 1.68 % $ 4.65 B chinaChina
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
-114 M - - $ 459 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
-26 M - -5.76 % $ 99.8 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
-21.8 M - 0.11 % $ 419 M usaUSA
Shineco, Inc. Shineco, Inc.
TYHT
-6.63 M - -3.90 % $ 97.2 M chinaChina
Intec Pharma Ltd Intec Pharma Ltd
NTEC
-14.1 M - -12.45 % $ 17.7 M israelIsrael
Progenity, Inc. Progenity, Inc.
PROG
-193 M - -3.47 % $ 164 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
-45.1 M - 1.52 % $ 136 M usaUSA
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
-16.3 M - -1.19 % $ 28.7 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
14.5 M - -6.63 % $ 13.9 M usaUSA
I-Mab I-Mab
IMAB
-1.47 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
603 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
67.3 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-17 M - -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
162 M - - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
-40 M - 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
-8.5 M - - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
-6.38 M - -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
-190 M - 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
-106 M - -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
-102 M - -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
-40.9 M - - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
-608 M - - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
321 M - - $ 1.83 B belgiumBelgium
Teligent, Inc. Teligent, Inc.
TLGT
-25.1 M - -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
-151 M - - $ 2.91 B usaUSA
Aphria Inc. Aphria Inc.
APHA
-84.6 M - -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
-4.32 M - -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
-74.8 M - -6.00 % $ 238 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
-57.4 M - - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
16.8 M - 0.38 % $ 12.9 M israelIsrael
Cerecor Inc. Cerecor Inc.
CERC
-63.5 M - -1.68 % $ 283 M usaUSA
Constellation Pharmaceuticals, Inc. Constellation Pharmaceuticals, Inc.
CNST
-126 M - - $ 1.63 B usaUSA
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
-8.2 M - -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
-113 M - 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
-228 K - 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
-58.1 M - - $ 6.81 B britainBritain
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
-109 M - - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
622 K - - $ 256 M canadaCanada
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
-16.9 M - -2.54 % $ 57.2 M usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
-126 M - -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
-633 M - -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
-79.6 M - -10.74 % $ 89.9 M usaUSA